Medical Condition News

RSS

Values-based approach for making more effective New Year's Resolutions

Dr. Richard Blonna, author, life coach, and stress management expert, offers a simple, values-based approach for making more effective New Year's Resolutions.

23 Dec 2010

Dieting trends in 2011

As the hectic holiday season comes to a close and a new year approaches, many consumers are once again vowing to adopt weight loss goals to shed those unwanted pounds. But with obesity increasing at alarming levels across the globe, a number of health experts are urging a new approach to help fight the nation's burgeoning weight problem.

23 Dec 2010

Earlier diagnosis in Cowden syndrome patients predisposed to breast and kidney cancer

Researchers at Cleveland Clinic's Genomic Medicine Institute have revealed multiple genetic discoveries that may permit easier diagnosis and disease management for Cowden syndrome patients who are predisposed to breast and kidney cancer.

23 Dec 2010

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Clinical Data, Inc., today announced that Santen Pharmaceutical Co., Ltd., has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Clinical Data's highly selective adenosine A2A agonist, ATL313, for the indication of primary open angle glaucoma and ocular hypertension.

From Santen Pharmaceutical Co., Ltd. 23 Dec 2010

Procognia grants Euro-Diagnostica license to provide diagnostic services for gastric cancer

Procognia is proud to announce that yesterday it signed a binding memorandum of understanding with Euro-Diagnostica (ED), a European diagnostic company that currently operates in the Scandinavian and Benelux markets, and is expected to expand its activity into other markets which may include Germany, Austria, Switzerland, and the UK in the near future.

23 Dec 2010

Promising initial data from STABLE clinical trial for endovascular treatment of Type B aortic dissection

Study investigators reported positive steps in Cook Medical's efforts to gain FDA approval of the treatment assessed in the STABLE clinical trial, designed to evaluate the safety and efficacy of a proximal endograft and a distal uncovered stent for the endovascular treatment of Type B aortic dissection for purposes of seeking FDA approval. The findings were presented by Dr. Joseph Lombardi at the 37th annual VEITHsymposium.

23 Dec 2010

St. Luke’s second in nation to perform EVAR with Endurant AAA Stent Graft System

An 80-year-old patient at St. Luke's Episcopal Hospital (St. Luke's) in Houston became the second in the nation to be treated with a newly approved FDA device for an abdominal aortic aneurysm (AAA). The condition, often called, "the silent killer," is a dangerous bulge or ballooning in the main artery of the body that typically causes no symptoms until it ruptures.

23 Dec 2010

Scientist discovers molecular switch controlling synthesis of ribosomes

A scientist from the Florida campus of The Scripps Research Institute has discovered a molecular switch that controls the synthesis of ribosomes. Ribosomes are the large machineries inside all living cells that produce proteins, the basic working units of any cell. These new findings offer a novel target for potential treatments for a range of diseases, including cancer.

23 Dec 2010

Key to long-term weight-loss success is finding unique individual level of carbohydrate tolerance

Recent media coverage suggests that the reported wedding diet of Carole Middleton, mother of future British princess Kate Middleton, is something brand new. Yet the Dukan Diet is just another variation of the Atkins Diet™, but with some nutritional recommendations that simply don't make sense or are guaranteed to fail.

23 Dec 2010

Liberty Dialysis and Renal Advantage to form the third largest dialysis provider in the U.S.

Liberty Dialysis and Renal Advantage today announced that the deal to form the 3rd largest dialysis provider in the U.S. has closed. The transaction was completed on December 17, 2010. The new company has 5,300 employees serving more than 19,000 patients in 260 locations in 32 states.

23 Dec 2010

Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it has initiated a controlled two-arm Phase 2b clinical study of Azixa (verubulin) as a front-line treatment for glioblastoma multiforme (GBM).

23 Dec 2010

Obese people more likely to report exercise as a trigger for asthma

Obese people are more likely to report exercise as a trigger for asthma. Of 673 people evaluated in a new study whose results are published in the journal The Physician and Sportsmedicine, 71 percent of participants reported exercise-induced asthma (ETA).

23 Dec 2010

Gilead stops ARTEMIS-IPF ambrisentan Phase III clinical trial in idiopathic pulmonary fibrosis

Gilead Sciences, Inc. today announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive ambrisentan.

23 Dec 2010

Fried fish consumption may increase risk of stroke

People living in the "stroke belt" states eat more fried fish than people living in the rest of the country, which may contribute to the high rate of death from stroke in those states, according to a study published in the December 22, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

23 Dec 2010

Research: Arsenic trioxide may benefit individuals with connective brain tumors

Arsenic is usually thought of as a poison. Despite this, it has been used in medicine for over 2000 years, and the arsenic compound arsenic trioxide (ATO) is FDA approved for the treatment of acute promyelocytic leukemia.

23 Dec 2010

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

Certain drugs may block tumor host interactions but do not destroy cancer cells

A class of drugs thought to kill cancer cells may in fact block "cross talk" between the cancer cell and normal immune cells, resulting in reduced cancer growth and spread-a discovery that could significantly alter the way cancer drugs are evaluated in the future.

23 Dec 2010

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.

23 Dec 2010

Patients with over expression of P-Rex1 protein are more likely to develop cancer metastasis

Overexpression or hyperactivation of ErbB cell-surface receptors drives the growth of many breast cancers. Drugs, like Herceptin, that block the receptors' signals halt tumor progression in some patients.

23 Dec 2010

New study reveals statin therapy linked to reduced postoperative mortality

Statin drugs were first introduced to lower blood cholesterol concentrations; however, research is now discovering other benefits. A new study from France, published in the January 2011 issue of Anesthesiology, is the first to analyze the impact of preoperative chronic statin therapy on postoperative adverse events in surgical patients. Findings from the study suggest that statin therapy is associated with reduced postoperative mortality.

23 Dec 2010

Medical Condition News

Values-based approach for making more effective New Year's Resolutions

Dieting trends in 2011

Earlier diagnosis in Cowden syndrome patients predisposed to breast and kidney cancer

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Procognia grants Euro-Diagnostica license to provide diagnostic services for gastric cancer

Promising initial data from STABLE clinical trial for endovascular treatment of Type B aortic dissection

St. Luke’s second in nation to perform EVAR with Endurant AAA Stent Graft System

Scientist discovers molecular switch controlling synthesis of ribosomes

Key to long-term weight-loss success is finding unique individual level of carbohydrate tolerance

Liberty Dialysis and Renal Advantage to form the third largest dialysis provider in the U.S.

Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM

Obese people more likely to report exercise as a trigger for asthma

Gilead stops ARTEMIS-IPF ambrisentan Phase III clinical trial in idiopathic pulmonary fibrosis

Fried fish consumption may increase risk of stroke

Research: Arsenic trioxide may benefit individuals with connective brain tumors

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Certain drugs may block tumor host interactions but do not destroy cancer cells

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

Patients with over expression of P-Rex1 protein are more likely to develop cancer metastasis

New study reveals statin therapy linked to reduced postoperative mortality

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Latest News